ACBM Stock Overview
Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Acro Biomedical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.10 |
| 52 Week High | US$4.25 |
| 52 Week Low | US$0.10 |
| Beta | 0.80 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.99% |
| 3 Year Change | -95.88% |
| 5 Year Change | -97.38% |
| Change since IPO | -95.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACBM | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.7% |
| 1Y | -97.0% | 3.5% | 26.0% |
Return vs Industry: ACBM underperformed the US Healthcare industry which returned 0.9% over the past year.
Return vs Market: ACBM underperformed the US Market which returned 20.6% over the past year.
Price Volatility
| ACBM volatility | |
|---|---|
| ACBM Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACBM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ACBM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Richard Chu | acrobiomedicalco.com |
Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products. It is involved in the development and sale of cordyceps, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd.
Acro Biomedical Co., Ltd. Fundamentals Summary
| ACBM fundamental statistics | |
|---|---|
| Market cap | US$6.30m |
| Earnings (TTM) | -US$15.15m |
| Revenue (TTM) | US$360.00k |
17.5x
P/S Ratio-0.4x
P/E RatioIs ACBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACBM income statement (TTM) | |
|---|---|
| Revenue | US$360.00k |
| Cost of Revenue | US$296.00k |
| Gross Profit | US$64.00k |
| Other Expenses | US$15.21m |
| Earnings | -US$15.15m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 17.78% |
| Net Profit Margin | -4,207.18% |
| Debt/Equity Ratio | 23.3% |
How did ACBM perform over the long term?
See historical performance and comparison